These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2005-005563-28 PRevention of Atherosclerosis In High-Risk Patients: Aggressive Risk Modification including NiAspan 2010-07-19 due-trials
Ongoing 2005-006097-10 Pilot study of dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esoph... not-yet-due
Ongoing 2005-006098-29 Prospektiv, randomisierte, doppelblinde, multizentrische Phase-II- Studie zum Vergleich der Wirksamkeit einer Chemotherapie mit Gemcitabin plus Cisplatin und Sorafenib (BAY 43-9006) versus Gemcitabin ... not-yet-due
Ongoing 2006-000799-33 A Study of the efficacy and safety of Rizatriptan 10 mg PRD in the treatment of acute migraine in patients with non satisfactory response to previous pharmacologic treatment not-yet-due
Not reported 2006-001641-33 Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome 2018-03-31 due-trials
Not reported Terminated 2006-006824-20 Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Pheochromocytoma – proof of concept study 2009-10-01 due-trials
Not reported Terminated 2006-007036-95 Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Prolactinomas - proof of concept study 2009-12-17 due-trials
Completed, but no date, and reported results 2007-000460-24 Bi-weekly Cetuximab combined with FOLFOX-6 as first-line treatment in metastatic colorectal cancer patients with wild-type k-ras status bad-data
Completed, but no date Terminated 2007-002036-28 Prospektive, randomisierte, kontrollierte, unizentrische, offene, Studie zur Thromboembolieprophylaxe mit Enoxaparin bei nicht-chirurgischen onkologischen Patienten unter systemischer antineoplasti... bad-data
Completed, but no date Terminated 2008-007609-36 Prospektiv randomisierte multizentrische Phase II-Studie zur Metastasenresektion von Lungenfiliae (poor-prognosis) beim klarzelligen Nierenzellkarzinom +/- adjuvante Sunitinibtherapie über 1 Jahr - SM... bad-data
Not reported Terminated 2008-008555-41 Comparative study of the effect of intranasal insulin on memory deficits in type 2 diabetes and early Alzheimer´s dementia (INSULA) 2015-03-02 due-trials
Not reported 2009-011354-18 Randomised, open-label, comparative phase IV study on the bioavailability of Ciclosporin Pro (Teva) versus Sandimmun® Optoral (Novartis) under fasting versus fed conditions in patients with stable ren... 2012-12-31 due-trials
Not reported 2009-016966-97 Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized, Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients with Cold Agglutinin Disease Usi... 2014-09-30 due-trials
Not reported 2010-022687-12 A Randomized Discontinuation, Blinded, Placebo-Controlled, Phase II Study of Sorafenib in Patients with Chemonaïve Metastatic Uveal Melanoma 2016-12-16 due-trials
Not reported 2011-001963-37 Randomized Phase II Trial of Three-weekly Cisplatinum and Pemetrexed versus Split-dose d1 and d8 Cisplatinum and Pemetrexed In Advanced and Inoperable Non-squamous Non-small-cell lung cancer (NSCLC) 2017-07-07 due-trials
Completed, but no date 2011-006204-13 Efficacy and safety of oral prednisone as add-on therapy in the prophylactic treatment of episodic cluster headache: a randomized, placebo controlled parallel study. bad-data
Exempt 2012-001891-13 Lenalidomide in conjunction with methotrexate, leucovorin, cytarabine and rituximab for the treatment of relapsed or refractory CD20-positive aggressive lymphomas: an open-label, multicenter phase I/I... not-yet-due
Not reported Terminated 2012-005569-10 Biopsy- and biology-driven optimization of targeted therapy of metastatic melanoma in BRAF inhibitor non-pretreated and pretreated subjects with advanced, non-resectable (Stage IIIC) or metastatic ... 2018-08-15 due-trials
Ongoing 2013-000043-78 Prospective randomized trial of an adjuvant therapy of completely resected Merkel Cell Carcinoma (MCC) with immune checkpoint blocking antibodies (Nivolumab, Opdivo®; Ipilimumab, Yervoy®) versus obser... not-yet-due
Exempt 2013-004458-34 A Phase I/II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Nintedanib/Vargatef in Combination With Paclitaxel Chemotherapy for Treatment of Pat... 2019-10-17 not-yet-due
Completed, report not yet due Terminated 2013-005503-13 A prospective randomized single blind monocenter phase II study of organ perfusion with Custodiol-N compared with Custodiol solution in living donor kidney transplantation 2019-08-13 not-yet-due
Reported results 2014-000599-24 Molecularly stratified parallel group phase II trial of the phosphoinositide 3-kinase (PI3K) inhibitor BKM120 in combination with tamoxifen in patients with hormone receptor-positive, HER2-negative in... 2017-10-18 due-trials
Ongoing 2014-001167-12 A Phase II Randomized, Double-Blind Trial of Immunotherapy with Nivolumab or Nivolumab plus Ipilimumab versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanoma w... not-yet-due
Ongoing 2014-001959-24 BoTN: Onabotulinumtoxin A for the treatment of trigeminal neuralgia: Efficacy, safety and neurophysiological alterations under therapy – a prospective, controlled trial not-yet-due
Completed, report not yet due 2014-004981-52 Nab-Paclitaxel (Abraxane®) and Gemcitabine as first line therapy in patients with cholangiocarcinoma ineligible for cisplatin-based chemotherapy – a pilot study 2019-10-10 not-yet-due
Ongoing 2015-002285-23 Phase 2 trial of ponatinib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) following failure or intolerance of prior therapy with imatinib (POETIG trial – POnatin... not-yet-due
Ongoing 2015-005097-37 A phase II, multicenter, open-label, randomized-controlled trial evaluating the efficacy and safety of a sequencing schedule of cobimetinib plus vemurafenib followed by immunotherapy with an anti- PD-... not-yet-due
Ongoing 2016-002941-49 Enhancing Radioiodine Incorporation into Radio Iodine Refractory Thyroid Cancers with MAPK Inhibition: A single center pilot study not-yet-due
Ongoing 2017-005121-21 Exploring the theragnostic value of osimertinib in EGFR-mutated lung cancer (THEROS) - A multicentric phase II study in patients with TKI-resistant EGFR-mutated lung cancer exhibiting early metabolic ... not-yet-due
Ongoing 2018-000383-28 Perioperative chemotherapy vs. immunotherapy vs. chemo-immunotherapy stratified by early response evaluation in patients with advanced gastric cancer (GC) and adenocarcinoma of the esophago-gastric ju... not-yet-due
Ongoing 2019-000058-77 Prospective Phase-II Trial of induction chemotherapy and chemoradiotherapy plus/minus the PD-L1 antibody durvalumab followed by surgery or definitive chemoradiation boost and consolidation durvalumab ... not-yet-due
Ongoing 2019-002478-29 Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung) not-yet-due